Chief Scientific Advisor, Renovacor, Inc., Director, Translational Science Laboratory @ RENOVACOR public offering, NYSE RCOR, September 2021; bought by Rocket Pharmaceu
Founder and Director; Renovacor, Inc., a cardiovascular gene therapy company for rare disease @ Renovacor completed A Round finaincing of $11 million to complete IND-enabling
Chairman AND FOUNDER @ Renovacor, Inc
Editor @ Journal of Clinical and Translational Science
Executive Dean, Temple School of Medicine, Chief Academic Officer Temple Health System @ Temple University
Louisiana State University School of Medicine in Shreveport
Doctor of Medicine (M.D.)
1977 - 1981
The Johns Hopkins University School of Medicine
Postdoctoral Fellow (Physiology)
1974 - 1977
University of Maryland
Doctor of Philosophy (Ph.D.) (Physiology)
1970 - 1974
Gettysburg College
Bachelor's Degree (liberal arts)
1966 - 1970
Arthur Feldman's Skills
Medicine
Molecular Biology
Clinical Research
Research
Healthcare
Medical Education
Life Sciences
Laboratory
Clinical Trials
Public Health
Arthur Feldman's Summary
Arthur Feldman, based in Philadelphia, PA, US, is currently a Renovacor, Inc. at Bought by ROCKET Pharmaceuticals, bringing experience from previous roles at Lewis Katz School of Medicine at Temple University, RENOVACOR public offering, NYSE RCOR, September 2021; bought by Rocket Pharmaceu, Renovacor completed A Round finaincing of $11 million to complete IND-enabling and Renovacor, Inc. Arthur Feldman holds a 1984 - 1986 The Johns Hopkins Hospital. With a robust skill set that includes Medicine, Molecular Biology, Clinical Research, Research, Healthcare and more, Arthur Feldman contributes valuable insights to the industry. Arthur Feldman has 3 emails on RocketReach.